Overexpressed tumor antigens, such as PSMA, are targets of novel PET imaging approaches1 as well as precision therapeutics (177Lu-PSMA-617) in mCRPC (https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf). Here, FOLH1 is linked to neoplasm.